These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33234845)

  • 1. Hemophagocytic lymphohistiocytosis of a melanoma patient under BRAF/MEK-inhibitor therapy following anti-PD1 inhibitor treatment: a case report and review to the literature.
    Dudda M; Mann C; Heinz J; Schmidgen I; Weid F; Kühn M; Saloga J; Grabbe S; Loquai C
    Melanoma Res; 2021 Feb; 31(1):81-84. PubMed ID: 33234845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemophagocytic lymphohistiocytosis in advanced melanoma treated with dabrafenib and trametinib combination: two cases.
    Samaran Q; Belakebi D; Theret S; Becquart O; Girard C; Du Thanh A; Guillot B; Lesage C; Dereure O
    Melanoma Res; 2020 Oct; 30(5):519-523. PubMed ID: 32784332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemophagocytic lymphohistiocytosis with advanced malignant melanoma accompanied by ipilimumab and nivolumab: A case report and literature review.
    Mizuta H; Nakano E; Takahashi A; Koyama T; Namikawa K; Yamazaki N
    Dermatol Ther; 2020 May; 33(3):e13321. PubMed ID: 32191382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma].
    Fauviaux E; Promelle V; Boucenna V; Jany B; Errera MH; Delbarre M; Boucenna W
    J Fr Ophtalmol; 2022 Jun; 45(6):612-618. PubMed ID: 35501194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report.
    Sadaat M; Jang S
    J Immunother Cancer; 2018 Jun; 6(1):49. PubMed ID: 29871698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hemophagocytic lymphohistiocytosis caused by hematogenous disseminated pulmonary tuberculosis: A case report].
    Li QY; Liang Y; Dai NN; Wang YX; Zhu BT; Wu R; Zhu H; Sun YC
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 54(6):1219-1223. PubMed ID: 36533359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
    Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
    Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
    Geukes Foppen MH; Boogerd W; Blank CU; van Thienen JV; Haanen JB; Brandsma D
    Melanoma Res; 2018 Apr; 28(2):126-133. PubMed ID: 29356790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
    Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
    Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IFN-α induced systemic lupus erythematosus complicated with hemophagocytic lymphohistiocytosis: a case report and literature review.
    Zeng Z; Tu W; Ji B; Liu J; Huang K; Nie D; Yang L
    Front Immunol; 2023; 14():1223062. PubMed ID: 37600795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
    Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B
    Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.
    Atkins MB; Tarhini A; Rael M; Gupte-Singh K; O'Brien E; Ritchings C; Rao S; McDermott DF
    Immunotherapy; 2019 May; 11(7):617-629. PubMed ID: 30852924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma.
    Park JJ; Hawryluk EB; Tahan SR; Flaherty K; Kim CC
    JAMA Dermatol; 2014 Mar; 150(3):307-11. PubMed ID: 24352115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS.
    Liu X; Zhu X; Zhou X; Xie Y; Xiang D; Wan Z; Huang Y; Zhu B
    Front Immunol; 2022; 13():1012643. PubMed ID: 36263041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
    Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P
    JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor.
    Galliker NA; Murer C; Kamarashev J; Dummer R; Goldinger SM
    Eur J Dermatol; 2015 Apr; 25(2):177-80. PubMed ID: 25788221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF and MEK inhibition in melanoma.
    Dossett LA; Kudchadkar RR; Zager JS
    Expert Opin Drug Saf; 2015 Apr; 14(4):559-70. PubMed ID: 25648338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemophagocytic lymphohistiocytosis in patients with metastatic malignant melanoma.
    Stabler S; Becquart C; Dumezy F; Terriou L; Mortier L
    Melanoma Res; 2017 Aug; 27(4):377-379. PubMed ID: 28471834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatal case of hemophagocytic lymphohistiocytosis associated with group B streptococcus sepsis: A case report.
    Choi YB; Yi DY
    Medicine (Baltimore); 2018 Oct; 97(40):e12210. PubMed ID: 30290591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.